Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms 2Lymphoma 2Glioma 2Brain Neoplasms 2Leukemia, Lymphoid 1Disease Progression 1

Interventions

Temozolomide 41Radiotherapy 15Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 10Bevacizumab 10Irinotecan 9Radiation 8Nivolumab 7Carmustine 7Specimen Handling 6Radiosurgery 6Carboplatin 6ribociclib 5O(6)-benzylguanine 5Imiquimod 5IL13-PE38 5Flucytosine 5Filgrastim 5Erlotinib Hydrochloride 5Cyclophosphamide 5Aminolevulinic Acid 5vandetanib 4sargramostim 4Topotecan 4Lomustine 4Imatinib Mesylate 4Etoposide 4Craniotomy 4vocimagene amiretrorepvec 3temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Glioma × enzastaurin × Clear all
NCT00108056 2019-12-05

Enzastaurin to Treat Recurrent Brain Tumor

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
26 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Disease Progression

NCT01445119 2013-08-28

A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas

Eli Lilly and Company

Phase 1 Completed
58 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡